{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:41:18Z","timestamp":1788795678391,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trimethylamine N-oxide (TMAO)-related metabolites are associated with the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) and are known to disrupt lipid metabolism. The aims of this study were to evaluate the associations between TMAO-related metabolites and blood lipids and determine how lowering the lipid profile via rosuvastatin therapy influences TMAO-related metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 112 patients with suspected ASCVD were enrolled in this study. The levels of plasma TMAO-related metabolites, including TMAO, choline, carnitine, betaine, and \u03b3-butyrobetaine (GBB), were analyzed by stable isotope dilution liquid chromatography-tandem mass spectrometry (LC\/MS\/MS) before and after rosuvastatin therapy in all patients. Statistical methods were used to detect the associations between TMAO-related metabolites and blood lipids and determine how rosuvastatin therapy alters the levels of these metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A significant positive correlation was found between TMAO and triglycerides (TG) (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.303,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Furthermore, significant negative correlations were found between TMAO and high-density lipoprotein cholesterol (HDL-c) and between betaine and low-density lipoprotein cholesterol (LDL-c) (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.405 and\u2009\u2212\u20090.308, respectively, both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Compared to baseline, significantly lower TMAO levels and higher carnitine, betaine and GBB levels were observed after rosuvastatin therapy, while the lipids decreased significantly (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The significant correlation between TMAO and TG or between betaine and LDL-c disappeared after rosuvastatin therapy (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.050 and\u2009\u2212\u20090.172, respectively, both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). However, a significantly positive association between carnitine and TC and a negative association between carnitine and LDL-c or between betaine and TG were found after adjustment for sex, age, body mass index (BMI) and lipids (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that TMAO-related metabolites are significantly associated with blood lipids, although some of them are changed postrosuvastatin therapy. Lower TMAO and higher TMAO precursors were observed after rosuvastatin therapy compared to baseline. This study indicates that elevated TMAO precursors after rosuvastatin therapy and their potential impact on ASCVD should be considered in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-022-01673-3","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T09:03:34Z","timestamp":1658394214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaowei","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57\u201363.","journal-title":"Nature"},{"key":"1673_CR2","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","volume":"19","author":"RA Koeth","year":"2013","unstructured":"Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576\u201385.","journal-title":"Nat Med"},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrcardio.2016.183","volume":"14","author":"AL Jonsson","year":"2017","unstructured":"Jonsson AL, B\u00e4ckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79\u201387.","journal-title":"Nat Rev Cardiol"},{"key":"1673_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmet.2014.10.006","volume":"20","author":"RA Koeth","year":"2014","unstructured":"Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, et al. \u03b3-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20:799\u2013812.","journal-title":"Cell Metab"},{"key":"1673_CR5","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","volume":"64","author":"WH Tang","year":"2014","unstructured":"Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cardfail.2014.11.006","volume":"21","author":"WH Tang","year":"2015","unstructured":"Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21:91\u20136.","journal-title":"J Card Fail"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.atherosclerosis.2016.01.033","volume":"247","author":"K Skagen","year":"2016","unstructured":"Skagen K, Troseid M, Ueland T, Holm S, Abbas A, Gregersen I, et al. The carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis. Atherosclerosis. 2016;247:64\u20139.","journal-title":"Atherosclerosis"},{"key":"1673_CR8","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.jacc.2016.03.546","volume":"67","author":"V Senthong","year":"2016","unstructured":"Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol. 2016;67:2620\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1673_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-015-0129-8","volume":"14","author":"X Xiong","year":"2015","unstructured":"Xiong X, Liu H, Hua L, Zhao H, Wang D, Li Y. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis. 2015;14:127.","journal-title":"Lipids Health Dis"},{"key":"1673_CR10","doi-asserted-by":"crossref","unstructured":"Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 Inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc. 2017;6:e006347.","DOI":"10.1161\/JAHA.117.006347"},{"key":"1673_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.thromres.2019.02.028","volume":"177","author":"X Cheng","year":"2019","unstructured":"Cheng X, Qiu X, Liu Y, Yuan C, Yang X. Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells: a new link between trimethylamine N-oxide and atherosclerotic thrombosis. Thromb Res. 2019;177:110\u20136.","journal-title":"Thromb Res"},{"key":"1673_CR12","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/s41598-019-40638-y","volume":"9","author":"RH Chou","year":"2019","unstructured":"Chou RH, Chen CY, Chen IC, Huang HL, Lu YW, Kuo CS, et al. Trimethylamine N-oxide, circulating endothelial progenitor cells, and endothelial function in patients with stable angina. Sci Rep. 2019;9:4249.","journal-title":"Sci Rep"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3945\/jn.115.220103","volume":"146","author":"S Rohrmann","year":"2016","unstructured":"Rohrmann S, Linseisen J, Allenspach M, von Eckardstein A, M\u00fcller D. Plasma concentrations of trimethylamine-N-oxide are directly associated with dairy food consumption and low-grade inflammation in a German adult population. J Nutr. 2016;146:283\u20139.","journal-title":"J Nutr"},{"key":"1673_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","volume":"117","author":"J Fu","year":"2015","unstructured":"Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117:817\u201324.","journal-title":"Circ Res"},{"key":"1673_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541\u20136.","journal-title":"Nature"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12944-018-0939-6","volume":"17","author":"L Ding","year":"2018","unstructured":"Ding L, Chang M, Guo Y, Zhang L, Xue C, Yanagita T, et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis. 2018;17:286.","journal-title":"Lipids Health Dis"},{"key":"1673_CR17","doi-asserted-by":"publisher","first-page":"e21666","DOI":"10.1371\/journal.pone.0021666","volume":"6","author":"M Lever","year":"2011","unstructured":"Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al. Plasma lipids and betaine are related in an acute coronary syndrome cohort. Plos One. 2011;6:e21666.","journal-title":"Plos One"},{"key":"1673_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565\u20139.","journal-title":"Science"},{"key":"1673_CR19","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1038\/s41598-020-62261-y","volume":"10","author":"M Kummen","year":"2020","unstructured":"Kummen M, Solberg OG, Storm-Larsen C, Holm K, Ragnarsson A, Tr\u00f8seid M, et al. Rosuvastatin alters the genetic composition of the human gut microbiome. Sci Rep. 2020;10:5397.","journal-title":"Sci Rep"},{"key":"1673_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/joim.12328","volume":"277","author":"M Tr\u00f8seid","year":"2015","unstructured":"Tr\u00f8seid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277:717\u201326.","journal-title":"J Intern Med"},{"key":"1673_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.chom.2008.02.015","volume":"3","author":"PJ Turnbaugh","year":"2008","unstructured":"Turnbaugh PJ, B\u00e4ckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3:213\u201323.","journal-title":"Cell Host Microbe"},{"key":"1673_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature07336","volume":"455","author":"L Wen","year":"2008","unstructured":"Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455:1109\u201313.","journal-title":"Nature"},{"key":"1673_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480\u20134.","journal-title":"Nature"},{"key":"1673_CR24","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","volume":"368","author":"WH Tang","year":"2013","unstructured":"Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575\u201384.","journal-title":"N Engl J Med"},{"key":"1673_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.metabol.2015.03.008","volume":"64","author":"Y Kim","year":"2015","unstructured":"Kim Y, Keogh J, Clifton P. A review of potential metabolic etiologies of the observed association between red meat consumption and development of type 2 diabetes mellitus. Metabolism. 2015;64:768\u201379.","journal-title":"Metabolism"},{"key":"1673_CR26","doi-asserted-by":"crossref","unstructured":"Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins (Basel).\u00a02016;8:326.","DOI":"10.3390\/toxins8110326"},{"key":"1673_CR27","doi-asserted-by":"crossref","unstructured":"Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol Nutr Food Res. 2017;61.\u00a0PMID:27377678.","DOI":"10.1002\/mnfr.201770016"},{"key":"1673_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.atherosclerosis.2015.10.091","volume":"243","author":"DM Mueller","year":"2015","unstructured":"Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis. 2015;243:638\u201344.","journal-title":"Atherosclerosis"},{"key":"1673_CR29","doi-asserted-by":"publisher","first-page":"e0141738","DOI":"10.1371\/journal.pone.0141738","volume":"11","author":"C Missailidis","year":"2016","unstructured":"Missailidis C, H\u00e4llqvist J, Qureshi AR, Barany P, Heimb\u00fcrger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. Plos One. 2016;11:e0141738.","journal-title":"Plos One"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ab.2014.03.016","volume":"455","author":"Z Wang","year":"2014","unstructured":"Wang Z, Levison BS, Hazen JE, Donahue L, Li XM, Hazen SL. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal Biochem. 2014;455:35\u201340.","journal-title":"Anal Biochem"},{"key":"1673_CR31","doi-asserted-by":"crossref","unstructured":"Guasch-Ferr\u00e9 M, Hu FB, Ruiz-Canela M, Bull\u00f3 M, Toledo E, Wang DD, et al. Plasma metabolites from choline pathway and risk of cardiovascular disease in the PREDIMED (prevention with Mediterranean diet) study. J Am Heart Assoc.\u00a02017;6:e006524.","DOI":"10.1161\/JAHA.117.006524"},{"key":"1673_CR32","doi-asserted-by":"publisher","first-page":"e014328","DOI":"10.1161\/JAHA.119.014328","volume":"9","author":"V Menon","year":"2020","unstructured":"Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, et al. Impact of baseline glycemic control on residual cardiovascular risk in patients with diabetes mellitus and high-risk vascular disease treated with statin therapy. J Am Heart Assoc. 2020;9:e014328.","journal-title":"J Am Heart Assoc"},{"key":"1673_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/cclm-2016-0374","volume":"55","author":"T K\u00fchn","year":"2017","unstructured":"K\u00fchn T, Rohrmann S, Sookthai D, Johnson T, Katzke V, Kaaks R, et al. Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year. Clin Chem Lab Med. 2017;55:261\u20138.","journal-title":"Clin Chem Lab Med"},{"key":"1673_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.biopha.2017.11.016","volume":"97","author":"J Geng","year":"2018","unstructured":"Geng J, Yang C, Wang B, Zhang X, Hu T, Gu Y, et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK\/JNK pathway. Biomed Pharmacother. 2018;97:941\u20137.","journal-title":"Biomed Pharmacother"},{"key":"1673_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10753-015-0261-7","volume":"39","author":"A Mohammadi","year":"2016","unstructured":"Mohammadi A, Najar AG, Yaghoobi MM, Jahani Y, Vahabzadeh Z. Trimethylamine-N-oxide treatment induces changes in the ATP-binding cassette transporter A1 and scavenger receptor A1 in murine macrophage J774A.1 cells. Inflammation. 2016;39:393\u2013404.","journal-title":"Inflammation"},{"key":"1673_CR36","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manner\u00e5s-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850\u20138.","journal-title":"Nat Med"},{"key":"1673_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.gastro.2015.06.043","volume":"149","author":"DE Freedberg","year":"2015","unstructured":"Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors Alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149:883\u2013885.e889.","journal-title":"Gastroenterology"},{"key":"1673_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fmicb.2018.00530","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Song X, Zhou H, Zhou X, Xia Y, Dong X, et al. Gut microbiome associates with lipid-lowering effect of Rosuvastatin in vivo. Front Microbiol. 2018;9:530.","journal-title":"Front Microbiol"},{"key":"1673_CR39","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41586-020-2269-x","volume":"581","author":"S Vieira-Silva","year":"2020","unstructured":"Vieira-Silva S, Falony G, Belda E, Nielsen T, Aron-Wisnewsky J, Chakaroun R, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581:310\u20135.","journal-title":"Nature"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-022-01673-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T09:10:55Z","timestamp":1658394655000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-022-01673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1186\/s12944-022-01673-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered at\n                      \n                      (NCT02305862), abided by the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of Beijing Tiantan Hospital (Approval No: KY2014\u2013020-02). All patients in this study signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}